Broker recommendations for Sanofi
The Sanofi stock is rated at 1.409091 (on a scale 1-3, where 1 is ‘strong buy‘ and 3 is ‘strong sell‘) from Thursday 25 June, 2020 by a total of 22 brokers. This means that the consensus of the 22 different brokers is leaning toward to buy/moderate buy.
Sell
0 (0%) Underweight
0 (0%) Hold
8 (36.36%) Overweight
2 (9.09%) Buy
12 (54.55%)
Price target by analysts
The 19 latest analyst estimates, per Monday 3 August, 2020, show the following high, low and average price targets.
Target Average: 60.98 USD
Target High: 65.35 USD
Target Low: 50.26 USD
Drug giants in talks over vaccine volumes
Tuesday, 4 August 2020, 07:00:00
DRUG giants Sanofi and GlaxoSmithKline are in advanced discussions with the European Commission for the supply of up to 300 million doses of a…
— Herald Scotland
DOJ probes Sanofi, GSK over possible carcinogen in Zantac
Monday, 3 August 2020, 18:04:38
The theory is the drugs should not have been reimbursed by the government if they were unapproved, misbranded or adulterated, an expert said.
— STAT News
French firm Sanofi indicted over epilepsy drug
Monday, 3 August 2020, 14:19:24
The pharmaceutical giant is accused of manslaughter after babies died, but it denies wrongdoing.
— BBC
GSK and Sanofi in ‘advanced discussions’ with EU over Covid-19 vaccine
Monday, 3 August 2020, 13:22:00
Drugs giants GlaxoSmithKline and Sanofi today neared the completed a trio of key agreements to supply their Covid-19 vaccine, amid discussions with the EU. The pair said they are in “advanced discussions” with the European bloc to supply 300 million doses of their candidate, which uses Sanofi’s recombinant protein-based technology combined with GSK’s pandemic adjuvant system.
— Evening Standard
Sanofi under investigation on charges including manslaughter over Depakine
Monday, 3 August 2020, 12:57:00
Sanofi Aventis France added it had respected all its obligations regarding information provided on Depakine
— Business Standard
